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The genetic programs that promote retention of self-
renewing leukemia stem cells (LSCs) at the apex of
cellular hierarchies in acute myeloid leukemia (AML)
are not known. In a mouse model of human AML,
LSCs exhibit variable frequencies that correlate with
the initiating MLL oncogene and are maintained in
aself-renewingstatebya transcriptional subprogram
more akin to that of embryonic stem cells (ESCs) than
to that of adult stem cells. The transcription/chro-
matin regulatory factors Myb, Hmgb3, and Cbx5 are
critical components of the program and suffice for
Hoxa/Meis-independent immortalization of myeloid
progenitors when coexpressed, establishing the
cooperative and essential role of an ESC-like LSC
maintenance program ancillary to the leukemia-initi-
ating MLL/Hox/Meis program. Enriched expression
of LSC maintenance and ESC-like program genes in
normal myeloid progenitors and poor-prognosis
humanmalignancies links the frequency of aberrantly
self-renewing progenitor-like cancer stem cells
(CSCs) to prognosis in human cancer.
INTRODUCTION
The cancer stem cell (CSC) model posits that many human
malignancies consist of two functionally distinct cell types: (1)
CSCs, which are self-renewing cells with the capacity to initiate,
sustain, and expand the disease; and (2) non-self-renewing
progeny cells, derived from CSCs through differentiation, which
likely make up the bulk of the tumor and account for disease
symptomatology (Jordan et al., 2006; Clarke et al., 2006). For
malignancies to be cured, it may be necessary and sufficient
to exclusively eliminate CSCs. Consequently, there is consider-
able interest in further understanding the biological and molec-
ular properties of these cells, by comparison with both theirCnon-self-renewing downstream progeny and their normal adult
stem cell counterparts.
CSCs (also called tumor-propagating or tumor-initiating cells)
were first formally described in human acute myeloid leukemia
(AML) as rare cells that share an immunophenotype with normal
hematopoietic stem cells (HSCs) (Bonnet and Dick, 1997). This
paradigm has recently been substantially revised based on two
significant observations. First, in murine models of human
leukemia induced by the MLL-AF9 oncogene, self-renewing
leukemia stem cells (LSCs) may account for up to a quarter of
cells within the leukemia clone and exhibit mature myeloid immu-
nophenotypes (Somervaille and Cleary, 2006). A high frequency
of LSCs was also observed in Sfpi/ murine AMLs (Kelly et al.,
2007). Second, protocols that enhance engraftment of human
leukemia cells in xenogeneic transplant assays demonstrate
the presence of LSCs in leukemia cell subpopulations previously
considered to be devoid of them (Taussig et al., 2008).
Since LSCs may be more numerous and mature than originally
proposed, the nature and generality of the hierarchical organiza-
tion of malignancies has recently been questioned (Kelly et al.,
2007). However, consistent with the CSC model, only a subset
of AML cells have clonogenic potential in in vitro assays (Buick
et al., 1977; Somervaille and Cleary, 2006), and human AML blast
cells undergo differentiation in vivo to mature granulocytes
(Fearon et al., 1986), as may murine LSCs initiated by MLL-AF9
(Somervaille and Cleary, 2006). To further elucidate the hierar-
chical disposition of AML, a major goal is to identify transcrip-
tional programs, genes, and pathways that specifically correlate
with and promote the retention of LSCs within the self-renewing
compartment of leukemias (Clarke et al., 2006). It is not known
whether such LSC maintenance programs are synonymous
with programs responsible for leukemia initiation—for example,
Hoxa/Meis in MLL leukemogenesis (Ayton and Cleary, 2003;
Krivtsov et al., 2006; Wong et al., 2007). It is also not clear whether
they share features with transcriptional programs expressed in
adult or embryonic stem cells (ESCs) (Ben-Porath et al., 2008;
Wong et al., 2008) or whether there is a relationship with genes
and pathways implicated in the function of AML stem cells
such as NFkB, phosphatidylinositide-3-kinase, CTNNB1, Ptenell Stem Cell 4, 129–140, February 6, 2009 ª2009 Elsevier Inc. 129
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2003), and Junb (Steidl et al., 2006).
To address these issues, we investigated the genetic determi-
nants that maintain LSC frequencies and leukemia cell hierar-
chies using a mouse model that faithfully recapitulates many of
the pathologic features of AML induced by chromosomal trans-
locations of the MLL gene (Lavau et al., 1997; Somervaille and
Cleary, 2006), which occur in about 5%–10% of human AMLs
(Look, 1997). Confirming recent speculation that CSC frequency
may differ between distinct tumor types (Kelly et al., 2007;
Adams et al., 2007; Kennedy et al., 2007), LSC frequency in
AML was found to vary substantially according to the initiating
MLL oncogene. This feature, and the observation that LSC
frequency varies within the leukemia cell hierarchy, was used
to derive a transcriptional program for LSC hierarchical mainte-
nance. The program indicates that MLL LSCs are maintained
in a self-renewing state by co-option of a transcriptional program
that shares features with ESCs and is transiently expressed in
normal myeloid precursors rather than HSCs or mature neutro-
phils. Furthermore, the shared transcriptional features of LSCs,
ESCs, normal midmyeloid lineage cells, and a diverse set of
poor-prognosis human malignancies support the broader
conclusion that CSCs may be aberrantly self-renewing down-
stream progenitor cells whose frequency in human malignant
disease correlates with and dictates prognosis.
RESULTS
Distinct Molecular Subtypes ofMLL Leukemia
Are Associated with Different LSC Frequencies
and Leukemia Cell Hierarchies
LSC frequencies and leukemia cell hierarchies were character-
ized in cohorts of mice where AML had been initiated using
MLL oncogenes (MLL-AF9, MLL-ENL, MLL-AF10, MLL-AF1p,
and MLL-GAS7) that function through distinct molecular mecha-
nisms (Somervaille and Cleary, 2006; Lavau et al., 1997; DiMar-
tino et al., 2002; So et al., 2003a, 2003b) (see Table S1 available
online). Relative LSC frequencies were assessed by determining
AML colony-forming cell (CFC) frequencies in the spleen and
bone marrow (BM) of leukemic mice. AML CFCs are a surrogate
measure for LSCs in both MLL-AF9 leukemia (Somervaille and
Cleary, 2006) and other MLL leukemia molecular subtypes
(Figure S1), as shown by secondary transplantation of cells
derived from singly isolated colonies. In leukemic mice in which
AML had been initiated by MLL-ENL or MLL-AF9, the frequen-
cies of AML CFCs/LSCs in both spleen and BM were significantly
higher than in mice in which leukemia had been initiated by MLL-
AF10,MLL-AF1p, orMLL-GAS7 (Figure 1A and data not shown).
Concordant with these data, approximately seven times as many
MLL-AF1p leukemia cells were required to initiate secondary
AML by comparison withMLL-ENL leukemia cells in limit dilution
analyses (Figure 1B). FACS analyses showed that greater than
99.5% of BM cells in all leukemias expressed one or more
myeloid-specific antigens, whereas less than 0.5% of cells
were Lin (Table S2), demonstrating that LSCs in the different
molecular subtypes of AML are predominantly myeloid Lin+ cells.
There was also a marked disparity in the hierarchical organiza-
tion of the respective leukemias. Those initiated by MLL-AF10 or
MLL-AF1p displayed extensive mature myeloid lineage differen-130 Cell Stem Cell 4, 129–140, February 6, 2009 ª2009 Elsevier Inc.tiation (Figures 1C and 1D) that was part of the leukemia clone
(Figure S2), and were classified as either acute myeloproliferative
disease-like myeloid leukemia or acute myelomonocytic
leukemia according to the Bethesda criteria (Kogan et al.,
2002). Conversely, leukemias initiated by MLL-AF9 or MLL-ENL
showed less differentiation, and most (16 of 18) were classified
as acute monocytic leukemia (Table S3). Consistent with this,
their explanted colonies in CFC assays were significantly more
‘‘blast-like’’ (type 1, Lavau et al. [1997]), containing a higher
proportion of cells displaying immature cytological and functional
features (Figure 1E and data not shown). MLL-GAS7 leukemias
exhibited the lowest AML CFC frequencies but morphologic
appearances more akin to MLL-ENL and MLL-AF9 leukemias
(Figures 1A and 1D), indicating that functional and morphologic
features of AML cellular hierarchies are not necessarily corre-
lated. The spectrum of disease manifestations was not due to
variations in the frequency of distinct clones or the number of
retroviral integrations per clone (Figure S3). Therefore, leukemia
cell hierarchy and the frequency of self-renewing Lin+ LSCs
vary significantly according to the initiating MLL oncogene.
Derivation of a Genetic Program that Maintains MLL
LSCswithin the Self-Renewing Fraction of the Leukemia
Cell Hierarchy
A genetic program that distinguishes LSCs from their differenti-
ated progeny within leukemia cell hierarchies and promotes
maintenance of self-renewal was derived based on the hypoth-
esis that it would be (1) differentially expressed between leuke-
mias containing LSCs at high versus low frequencies and (2)
concordantly regulated in LSC-enriched versus LSC-depleted
cell populations within a given leukemia.
MLL leukemia molecular subtypes were therefore grouped
into two classes according to their relative LSC frequencies:
high LSC frequency leukemias (MLL-AF9 and MLL-ENL) and
low LSC frequency leukemias (MLL-AF10, MLL-AF1p, and
MLL-GAS7). Comparison of global transcriptional profiles in
34 distinct BM AML samples representative of these two groups
(12 and 22, respectively) revealed 2943 differentially expressed
probe sets (at significance level p % 0.01 [unpaired t test];
median false discovery rate [FDR] 12.3%; Figure 2A; Table S4).
Leukemia cells from mice with MLL-AF10 AML were then frac-
tionated intoseparatesubpopulationson the basisof c-kit expres-
sion, which correlates with MLL LSC frequency (Somervaille and
Cleary, 2006). The sorted AML subpopulations exhibited substan-
tial differences in their frequencies of AML CFCs/LSCs (mean
14-fold; Figure 2B) and morphologic features (Figure 2C), consis-
tent with a leukemia cell hierarchy with maturation through to
terminally differentiated neutrophils. Comparison of global tran-
scriptional profiles of the LSC-enriched (c-kithi) versus LSC-
depleted (c-kitlo) populations from within individual leukemias
revealed 5173 differentially expressed probe sets (at significance
level p% 0.01 [unpaired t test]; Figure 2D and Table S5).
The respective data sets from the above analyses were inter-
sected to identify core gene sets that positively or negatively
correlate with LSC potential (Figures 2E and 2F). Expression of
204 probe sets was found to be positively correlated with high
LSC frequency across the different molecular subtypes of MLL
leukemia and concordantly downregulated between LSC-
enriched versus LSC-depleted populations (Figure 2E and Table
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Figure 1. Variable LSC Frequencies and Cellular Hierarchies in Murine AMLs Induced by Different MLL Oncogenes
(A) Bar graph shows frequency of CFCs in the spleens of leukemic mice (mean ± SEM; n = 7 leukemias for each fusion, exceptMLL-GAS7, where n = 11; *p% 0.001
by comparison with MLL-AF9).
(B) Limit dilution analyses show the estimated number of secondarily transplanted leukemicMLL-ENL orMLL-AF1p splenocytes required to initiate AML in suble-
thally irradiated recipient mice (n = 8 recipients for each cell dose). Mice were followed for 180 days, with the longest disease latencies being 66 days forMLL-ENL
and 67 days for MLL-AF1p.
(C) In representative BM cytospin images, MLL-AF1p-initiated AML cells are more differentiated by comparison with MLL-ENL-initiated AML cells. Scale bar
applies to both images.
(D) Bar graph shows percentage cell type in spleen as determined by morphologic analysis of cytospin preparations (mean ± SEM; n = 8–13 for each cohort; *p%
0.05 for blast cell percentage versus MLL-AF9). Bl, blast cell; Mat, maturing myelomonocytic cell; Neu, neutrophil; Ly, lymphocyte; nRBC, nucleated erythroid
precursor cell.
(E) Bar graph shows proportion of myeloid leukemia colonies of each morphologic type (defined in Lavau et al., 1997) (mean ± SEM; n = 3–5 separate leukemias for
each fusion; *p < 0.05 by comparison withMLL-AF9 for type 1 colony frequency). Representative images are shown on the right. Scale bar applies to both images.S6). Conversely, the expression of 466 probe sets was negatively
correlated with LSC frequency across the different molecular
subtypes of MLL leukemia and concordantly upregulated
from LSC-enriched to LSC-depleted populations (Figure 2F
and Table S7; p < 0.001 for both intersections using Pearson’s
chi-square test). The 185 genes (204 probe sets) whose expres-
sion positively correlated with LSC frequency, along with the
375 genes (466 probe sets) whose downregulation correlated
with LSC frequency, are hereafter collectively termed the LSC
maintenance program.
LSCs in Murine MLL Myeloid Leukemia Are
Metabolically Active, Proliferating Cells
In contrast to the assumption that AML LSCs are predominantly
quiescent (Jordan et al., 2006), gene ontology (GO) annotations
of upregulated LSC maintenance program genes were consis-
tent with LSCs being metabolically active, cycling cells
(Figure 3A). Furthermore, gene set enrichment analysis (GSEA;
Subramanian et al., 2005) revealed significant enrichments of
expression of curated gene sets for cell cycle, metabolism,
and Myc targets in high LSC frequency cell populations by
comparison with their respective low LSC frequency populations
(Table S8). Cell-cycle analyses performed on AML subpopula-
tions sorted for different levels of c-kit expression (Figure 3B),
which correlates with LSC frequency (Figure 2B and SomervailleCand Cleary, 2006), showed that fractions containing the highest
frequency of LSCs also contained the highest proportion of
cycling cells (Figure 3B). Thus, LSCs in this model of AML are
predominantly metabolically active, cycling cells.
The LSC Maintenance Program Represents
a Committed Myeloid, as Opposed to an HSC,
Transcriptional Program
Upregulated LSC maintenance program genes displayed highest
relative expression during normal hematopoiesis in midmyeloid
lineage cells (granulocyte-macrophage progenitors and myelo-
blasts) versus lower levels in KSL (c-kit+ Sca1+ Lin) cells and
terminally differentiated neutrophils (Figure 3C and Figure S4).
Conversely, an inverse pattern of expression was observed for
genes negatively correlated with LSC potential (Figure 3D).
Thus, a critical effect of MLL oncogenes is to convert a normal
midmyeloid lineage program into an AML LSC maintenance
program. Consistent with these observations, GSEA revealed
that leukemia cell populations containing high frequencies of
LSCs exhibited enriched expressionof genesexpressed innormal
lineage-committed hematopoietic progenitors (Ivanova et al.,
2002), but not genes expressed in long-term HSCs (Table S8).
Notably, Hoxa and Meis1, which are prominently expressed in
KSL cells, did not feature in the LSC maintenance signature, nor
did KSL transcripts previously shown to be shared withMLL-AF9ell Stem Cell 4, 129–140, February 6, 2009 ª2009 Elsevier Inc. 131
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Figure 2. Derivation of an MLL LSC Mainte-
nance Signature
(A) Image represents the 2943 probe sets differen-
tially expressed between 12 high LSC frequency
AMLs (MLL-ENL and MLL-AF9) and 22 low LSC
frequency AMLs (MLL-AF1p, MLL-AF10 and
MLL-GAS7). Color scale indicates normalized
expression values.
(B) MLL-AF10 leukemic splenocytes were FACS
sorted for high- or low-level c-kit expression, as
indicated in the representative plot. Bar graph
shows clonogenic potentials of the sorted subpop-
ulations in semisolid culture (mean ± SEM; n = 4).
AML was initiated by transplantation of immortal-
ized CD45.2+ c-kit+ BM stem and progenitor cells.
(C) Bar graph and representative images show
morphology of sorted leukemia cell populations
(mean ± SEM; n = 4). Scale bar applies to both
images.
(D) Image represents the 5173 probe sets differen-
tially expressed between high LSC frequency
(c-kithi) and low LSC frequency (c-kitlo) MLL-AF10
leukemia cell subpopulations. Color scale indi-
cates normalized expression values.
(E and F) Venn diagrams show the intersection of
probe sets positively (E) and negatively (F) corre-
lated with LSC frequency from the analyses shown
in (A) and (D).LSCs (Krivtsov et al., 2006; Figure S5). Although required for
leukemic transformation of BM stem and progenitor cells by
MLL oncogenes (Ayton and Cleary, 2003; So et al., 2004;
Wong et al., 2007), Hoxa/Meis1 and Mef2c levels did not vary
concordantly with LSC frequency (Figure 3E). Indeed, sponta-
neous terminal leukemia cell differentiation and loss of self-
renewal potential in MLL-AF10 leukemias (Figures 2B and 2C)
occurred in the presence of substantially elevated Hoxa and
Meis1 expression, which did not vary significantly between
LSC-enriched and LSC-depleted subpopulations (Figure 3E).
Thus, MLL LSCs are metabolically active, aberrantly self-renew-
ing, committed myeloid cells, rather than HSCs aberrantly
expressing myeloid lineage antigens, and undergo loss of self-
renewal potential in vivo in the presence of relatively high-level
expression of Hoxa and Meis1 transcripts.
MLL LSCs Share Transcriptional Similarities with ESCs
and Poor-Prognosis Human Malignancies, Including
Pediatric Leukemia
Poor prognosis in a diverse set of human malignancies is associ-
ated with the expression of an ESC-like program (Wong et al.,
2008; Ben-Porath et al., 2008). GSEA demonstrated that expres-
sion of ESC-like program genes was substantially enriched in the
high versus low LSC frequencyMLL leukemia cell populations, in
contrast to the reverse enrichment of an adult stem cell core
program (Wong et al., 2008) in LSC-depleted populations
(Figure 4A and Table 1). Enrichment for an ESC-like program
was not driven by proliferation genes, since the significance of
the correlation was maintained when genes with cell-cycle-func-
tional annotations were excluded from the analysis (Table 1). The
ESC-like state in MLL LSCs was not induced by genes such as
Pou5f1, Nanog, or Sox2, which were not significantly expressed
(data not shown), nor coordinate expression of their downstream132 Cell Stem Cell 4, 129–140, February 6, 2009 ª2009 Elsevier Inctranscriptional effecters (Boyer et al., 2005), which were not
enriched in MLL LSCs (Table 1).
Expression of ESC-like program genes was also transiently
induced during normal myeloid differentiation, whereas expres-
sion of adult stem cell core genes was suppressed upon exit
from the KLS compartment (Figure 4B). This showed that the
normal midmyeloid program co-opted by MLL oncoproteins to
maintain LSCs in a self-renewing state exhibits shared features
with ESCs. Furthermore, expression of gene sets associated
with poor prognosis in a diverse set of human cancers, including
pediatric myeloid leukemia (Yagi et al., 2003), was enriched in
high versus low LSC frequency cell populations (Figure 4C and
Table 1). Taken together, these observations suggest a link
between prognosis in human cancer and the frequency of aber-
rantly self-renewing progenitor cells downstream of the tissue
stem cell (Figure 4D).
Genes that regulate transcription and chromatin are candidate
critical drivers of the shared transcriptional and biological prop-
erties of both self-renewing LSCs and ESCs. In a leading-edge
analysis of the expression of ESC-like program genes with tran-
scription or chromatin annotations in high versus low LSC
frequency populations (Figure 4E), there was prominent place-
ment of genes found within the LSC maintenance signature
(e.g., Hmgb3, Cbx5, Mtf2, Orc2l) or of genes with close homo-
logs within the signature (e.g., Mybl2, Ilf3). Thus, regulators of
transcription or chromatin, or their close homologs, that are
expressed in ESCs are also expressed in MLL LSCs.
Validation of the MLL Leukemia Maintenance Program
Indicates Critical Collaborative Roles for Myb, Cbx5,
and Hmgb3
To validate the role of the maintenance program in LSC self-
renewal, three transcription or chromatin regulators were.
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Figure 3. Biological Features of MLL LSCs
(A) GO analysis of upregulated LSC maintenance signature genes based on their biological process annotations.
(B) Mac1+ splenocytes from a mouse with MLL-AF9 AML were FACS sorted using the gates indicated in the representative plot. Sorted cells within each fraction
were then analyzed for their cell-cycle status (right hand plots).
(C and D) Unsupervised cluster analysis of the expression patterns of LSC maintenance signature genes positively (C) or negatively (D) correlated with LSC func-
tion, in defined populations of normal hematopoietic cells. Values from KSL, CMP, and GMP cells (Krivtsov et al., 2006) and normal myeloblasts and neutrophils
(this study) were utilized. Not all of the genes in the signature are represented on the Affymetrix 430A 2.0 chip used by Krivtsov et al. Color scale applies to both
images and represents normalized expression values.
(E) Heat map shows expression ofHoxa,Meis1, andMef2c genes in microarray analyses ofMLL leukemias with high or low frequencies of LSCs (left panel), and in
sorted subpopulations of MLL-AF10 leukemias with high (c-kithi) or low (c-kitlo) frequencies of LSCs (right panel). Expression values for whole BM (left panel) and
prospectively isolated normal myeloblasts or neutrophils (right panel) are shown for comparison (normal control).selected for further study:Myb, a transcription factor required for
in vitro transformation of murine BM progenitor cells by MLL-
ENL (Hess et al., 2006); Cbx5 (HP1a), an epigenetic repressor
that binds the histone H3-K9 methylation mark to promote
heterochromatin formation (Bannister et al., 2001); and Hmgb3,
a high-mobility group box protein that regulates self-renewal in
normal HSCs (Nemeth et al., 2006). Consistent with their poten-
tial roles in maintaining LSC self-renewal, the expression of all
three genes was substantially reduced concomitant with loss
of clonogenic activity and induction of macrophage differentia-Ction in transformed hematopoietic progenitors following inactiva-
tion of an MLL-ENL-ER-conditional oncoprotein (Ayton and
Cleary, 2003) by withdrawal of 4-hydroxytamoxifen (Figure 5A).
When assessed across 23 distinct AMLs,Myb transcript levels
correlated significantly with LSC frequencies (Figure 5B).
Furthermore, Myb knockdown reduced AML CFC/LSC frequen-
cies (Figure 5C) in direct proportion to the extent of knockdown
(Figure 5D) without inducing apoptosis (Figure S6), and surviving
colonies predominantly featured type 2 or type 3 morphology,
consistent with Myb reduction promoting terminal leukemiaell Stem Cell 4, 129–140, February 6, 2009 ª2009 Elsevier Inc. 133
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Figure 4. Shared Transcriptional Features of MLL LSCs, ESCs, Normal Myeloid Progenitors, and Poor-Prognosis Human Malignancies,
Including Pediatric Leukemia
(A) GSEA plots show that expression of an ESC-like core gene module (Wong et al., 2008; Table S9) is enriched in high (c-kithi) versus low (c-kitlo) LSC frequency
MLL-AF10 leukemia cell populations (left panel), whereas the reverse correlation is observed for an adult tissue stem cell module (right panel).
(B) Unsupervised cluster analysis of the expression pattern of ESC-like core module genes (left panel) and adult tissue stem cell module genes (right panel)
(Wong et al., 2008) in the indicated defined populations of normal hematopoietic cells (Krivtsov et al., 2006, and this study). Color scale indicates normalized
expression values.
(C) GSEA plots show expression of poor-prognosis genes in pediatric myeloid leukemia (Yagi et al., 2003; Table S9) is enriched in high (c-kithi) versus low (c-kitlo)
LSC frequency MLL-AF10 leukemia cell populations (left panel), whereas the reverse correlation is observed for good prognosis genes (right panel).
(D) Suggested link between an ESC-like transcriptional signature, prognosis, and CSC frequency in human malignancy.
(E) Leading-edge analysis of GSEA plot shows enriched expression of ESC-like genes with transcription or chromatin annotations (Ben-Porath et al., 2008; Table
S9) in high (c-kithi) versus low (c-kitlo) LSC frequency MLL-AF10 leukemia cell populations. Those marked with an asterisk, or their close homologs, are found
within the LSC maintenance signature.cell differentiation (Figures 5C and 5E). Mice secondarily trans-
planted with Myb knockdown AML cells displayed reduced
leukemia incidence (50%) with considerably longer latencies
compared to controls (Figure 5F). Knockdown of Cbx5 or
Hmgb3, but not three other upregulated LSC maintenance
program genes (E2f6, Serbp1, and Pebp1; data not shown),
also significantly reduced the frequency of AML CFCs/LSCs
(Figures 6A and 6B) in direct proportion to the degree of knock-
down (Figure 6C), also without inducing apoptosis (Figure S6).134 Cell Stem Cell 4, 129–140, February 6, 2009 ª2009 Elsevier IncBy contrast, enforced expression of genes negatively correlated
with LSC potential (Klf3, Klf13, but not Smad4; Figure S7) abro-
gated AML CFC/LSC potential.
Neither Myb, Cbx5, or Hmgb3, however, induced serial replat-
ing in semisolid culture when individually transduced into c-kit+
BM stem and progenitor cells (Figure 6D and data not shown).
The clonogenic potentials of transduced cells were either weakly
enhanced (Myb) or not enhanced (Cbx5 or Hmgb3) in the third
round of culture by comparison with cells transduced with.
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Gene Set Name
High versus Low LSC Frequency
AML Comparison (Figure 2A)
c-kithi versus c-kitlo
AML Comparison (Figure 2D)
NES FDR NES FDR
Stem Cell Gene Sets
CORE ESC-LIKE GENE MODULE (Wong et al., 2008) 1.69 0.02 1.75 0.03
CORE ESC-LIKE GENE MODULE WITHOUT
PROLIFERATION GENES
1.76 0.03 1.83 0.02
ADULT TISSUE STEM MODULE 1.13 0.36 1.74 0.03
ES expressed 1
(Assou et al., 2007; Ben-Porath et al., 2008)
1.26 0.19 1.66 0.03
ES expressed 2 (Ben-Porath et al., 2008) 1.52 0.09 1.58 0.03
NOS TFs (Boyer et al., 2005; Ben-Porath et al., 2008) 1.0 0.45 1.38 0.17
Human Cancer Gene Sets
YAGI_AML_PROGNOSIS (POOR PROG SET) 1.39 0.11 1.42 0.07
YAGI_AML_PROGNOSIS (GOOD PROG SET) 1.53 0.07 1.76 0.02
BRCA_PROGNOSIS_NEG 1.65 0.19 1.51 0.20
VANTVEER_BREAST_OUTCOME_GOOD_VS_POOR_DN 1.60 0.20 1.42 0.23
CANCER_UNDIFFERENTIATED_META_UP 1.43 0.26 1.54 0.19
ZHAN_MULTIPLE_MYELOMA_SUBCLASSES_DIFF 1.66 0.20 1.45 0.23
NES, normalized enrichment score. FDR, false discovery rate. NOS TFs, transcription factors regulated by Nanog, Pou5f1, and Sox2. Gene sets are
from the indicated publications (and listed in Table S9) or http://www.broad.mit.edu/gsea.control retroviruses. In pairwise combinations, Hmgb3 slightly
enhanced the weak third round clonogenic potentials induced
by expression of Myb alone, which was dramatically enhanced
by further addition of Cbx5. Thus, cells cotransduced by all three
genes displayed robust serial replating (Figure 6D and data not
shown). Colonies were exclusively type 1 and contained myelo-
blasts (c-kit+ Mac1+ Gr1+ immunophenotype) that readily adap-
ted to growth in liquid culture (data not shown). Effective bypass
of the upstream MLL transformation pathway was confirmed by
lack of Hoxa and Meis1 expression in cells immortalized by the
combined actions of Myb, Cbx5, and Hmgb3 (Figure 6E). Thus,
individual genes of the program are necessary but not sufficient
for LSC maintenance. However, they suffice for Hoxa/Meis1-
independent immortalization when simultaneously coexpressed,
thereby establishing their cooperative roles in the LSC mainte-
nance program.
DISCUSSION
The CSC model predicts that malignancies are organized into
cellular hierarchies characterized by differing self-renewal
potentials, such that a significant fraction of cells in the tumor
clone is incapable of self-renewal despite shared genetic
features with the CSC fraction (Clarke et al., 2006). Recent
studies, however, have demonstrated that CSCs may be consid-
erably more frequent than predicted by xenogeneic transplanta-
tion assays and have raised questions as to the validity and
generality of the CSC model as well as the existence and extent
of CSC hierarchical relationships (Kelly et al., 2007). Identifica-
tion of molecular pathways that regulate the self-renewing frac-
tion of CSCs within a malignancy would illustrate the nature of
potential CSC hierarchies and additionally hold out promise for
the development of therapies that specifically target the criticalCcellular components of malignant disease. Our current studies
demonstrate that MLL LSCs are actively cycling downstream
myeloid precursors occupying the apex of a leukemia cell hier-
archy, and maintained in a self-renewing state by a genetic
program more akin to embryonic than adult stem cells. This
contrasts with previous suggestions that LSCs are synonymous
with HSCs or exclusively maintained by corrupted HSC-specific
programs (Bonnet and Dick, 1997; Krivtsov et al., 2006). Despite
the downstream character of LSCs in this model of AML, our
studies provide unequivocal support for a hierarchical leukemia
cell organization and, in fact, further suggest that the relative
abundance of self-renewing cells in human cancers may be an
important prognostic factor.
MLL Oncogenes Differentially Specify LSC Hierarchies
and Frequencies
MLL oncogenes are structurally heterogeneous due to differ-
ences in their respective fusion partners, which have previously
been suggested to ‘‘instruct’’ certain biological properties of
leukemia such as disease latency and lineage of the leukemic
blasts (Lavau et al., 1997, 2000; Cano et al., 2007; Wong et al.,
2007). Consistent with this, our comparative analysis of several
molecularly distinct MLL oncogenes under identical experi-
mental conditions showed that MLL fusion partners determine
the frequencies of LSCs, which vary by up to 7-fold in a murine
model of AML. At a cellular level, this reflects the abilities of
MLL oncogenes to differentially specify the probability of self-
renewal versus differentiation, which in turn may directly affect
the cellular hierarchy and hematologic features of disease. At
a molecular level, this likely reflects quantitative and/or qualita-
tive differences in the transcriptional effecter functions of MLL
fusion partners, which sustain divergent global transcriptional
profiles that distinguish low versus high LSC frequency AMLs.ell Stem Cell 4, 129–140, February 6, 2009 ª2009 Elsevier Inc. 135
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Figure 5. Myb Is a Critical Component of the MLL LSC Maintenance Signature
(A) Bar graph (left panel) shows clonogenic potentials of c-kit+ BM stem and progenitor cells transformed by MLL-ENL-ER and then cultured in the presence or
absence of 4-OHT for seven days (mean ± SEM; n = 4). Bar graph (right panel) shows expression ofMyb,Cbx5, andHmgb3 transcripts in cells deprived of 4-OHT
by comparison with control cells exposed to 4-OHT (mean ± SEM; n = 4).
(B) Graph shows that Myb transcript levels (microarray expression value) correlate significantly with LSC frequencies (see Figure 1A) within individual leukemias
(n = 23 separate leukemias; n = 3–6 for each of the five MLL molecular subtypes in this study).
(C) Bar graph shows CFC potentials of MLL-ENL AML cells transduced with lentiviruses containing shRNA constructs targeting Myb or luciferase transcripts, by
comparison with control cells transduced with an empty lentivirus (MTV), stratified by colony types (indicated in the representative images; mean ± SEM; n = 4).
Transduced AML cells were FACS sorted for mCherry expression 48 hr following lentiviral transduction.
(D) Graph demonstrates that the extent of Myb knockdown measured by quantitative PCR in transduced cells 48 hr following lentiviral transduction correlated
significantly with the inhibition of AML CFC/LSC formation for each of the five Myb knockdown constructs.
(E) Bar graph (mean ± SEM; n = 4) and representative images show morphologic analysis of Myb knockdown and control MLL-ENL AML cells 48 hr following
transduction.
(F) Survival curves of sublethally irradiated syngeneic mice transplanted with 2.5–25 3 104 MLL-ENL AML cells transduced with lentiviruses targeting Myb or
luciferase expression.Our studies also provide support for the CSC model itself,
which has recently been questioned (Kelly et al., 2007). For
example, MLL-AF10 leukemic clones consisted of approxi-
mately 5% self-renewing LSCs as well as up to 35% terminally
differentiated mature neutrophils, reflecting previous reports of
neutrophilic differentiation within the leukemia clone in human
AML (Fearon et al., 1986). Our observation that LSC frequencies
in experimentally induced AML can vary substantially, even
when initiated by broadly similar oncogenes, provides direct
experimental confirmation of recent proposals (Adams et al.,
2007; Kennedy et al., 2007) and further suggests that variation
in LSC frequency may also be a feature of human leukemia.
Consistent with this, clonogenic cell frequencies vary over136 Cell Stem Cell 4, 129–140, February 6, 2009 ª2009 Elsevier Inca 1000-fold range (Buick et al., 1977) in AMLs, which also exhibit
markedly different engraftment abilities in immune-deficient
mice (Pearce et al., 2006), a functional readout of LSC potential.
Thus, AMLs are hierarchically organized, but the LSC compart-
ment is not necessarily a numerically fixed, prospectively defin-
able cellular subfraction.
The Biology of MLL LSCs Is Informed by Their
Maintenance Signature
LSCs can be partially enriched based on immunophenotypic and
other markers, but current approaches do not enable their
prospective isolation to levels of purity comparable with those
achieved for isolation of normal murine HSCs. Thus, as an.
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Figure 6. Requirement of Hmgb3 and Cbx5 for the Cooperative Maintenance of MLL LSC Potentials
(A and B) Bar graph shows clonogenic/LSC potentials (mean ± SEM) of MLL-ENL AML cells transduced with lentiviruses containing shRNA constructs targeting
Cbx5,Hmgb3, or luciferase expression, by comparison with control cells transduced with an empty lentivirus (MTV). Transduced AML cells were FACS sorted for
mCherry expression 48 hr following lentiviral infection. Colony types are indicated (A), and representative images are shown (B). Scale bar applies to all images.
(C) Graphs demonstrate that the extent of Cbx5 and Hmgb3 knockdown measured by quantitative PCR in transduced cells 48 hr following lentiviral transduction
correlated with the inhibition of AML-CFC/LSC potential.
(D) Bar graph shows serial replating potentials of c-kit+ BM stem and progenitor cells triple cotransduced with all possible combinations of Myb, Cbx5, Hmgb3,
and control viruses. Mneo, MSCV Neo; Mpuro, MSCV Puro; MIrG, MSCV IRES-GFP.
(E) Bar graph shows relative expression of Hoxa7, Hoxa9, and Meis1, as determined by quantitative PCR, in prospectively sorted normal murine BM progenitor
subsets (CMP, GMP, and c-kit+ Mac1+ myeloblasts) and in c-kit+ BM stem and progenitor cells immortalized by the indicated oncogenes, or coexpression of
Myb, Cbx5 and Hmgb3 (HCM, three separate lines are shown).alternative approach to identify a transcriptional program that
defines LSCs, and because cell-type-specific transcripts from
minority cell populations can readily be detected in bulk tumor
samples (Perou et al., 2000), we intersected gene sets correlating
with LSCfrequency derived from twodifferent experimentalmeth-
odologies (Figures 2A and 2D), each associated with low FDRs.
The derived LSC maintenance program revealed several novel
attributes of MLL LSCs. In contrast to the prevailing notion that
AML LSCs are predominantly quiescent (Jordan et al., 2006),
MLL LSCs are predominantly metabolically active, cycling cells
as demonstrated by GO and GSEA analyses of the signature,
and confirmed experimentally by cell-cycle analysis of sorted
leukemia cell subpopulations. Furthermore, upregulated LSC
maintenance program genes are maximally expressed at a mid-
myeloid stage during normal differentiation (GMPs and myelo-
blasts) and mostly downregulated in mature neutrophils and theKSL compartment, which contains HSCs. Together with the
observation that MLL LSC transcriptional profiles are enriched
for expression of gene sets expressed in normal lineage-
committed hematopoietic progenitor cells rather than long-term
HSCs, these data emphasize that the LSC in MLL leukemias is
an aberrantly self-renewing downstream myeloid cell, rather
than a tissue stem cell aberrantly expressing myeloid lineage
antigens (Passegue et al., 2003; Somervaille and Cleary, 2006).
AlthoughHoxa andMeis1 expression is induced by MLL onco-
proteins (Krivtsov et al., 2006) and required for initiation of MLL
leukemia (Ayton and Cleary, 2003; So et al., 2004; Wong et al.,
2007), these genes were not part of the LSC maintenance
program because their expression levels did not vary concor-
dantly between leukemia cell populations containing different
frequencies of LSCs. Indeed, MLL-AF10 LSCs underwent
terminal granulocytic differentiation with concomitant loss ofCell Stem Cell 4, 129–140, February 6, 2009 ª2009 Elsevier Inc. 137
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Hoxa and Meis1 transcript levels, although the possibility of
posttranslational regulation is not excluded. However, there is
also no overlap of the maintenance program with a KSL/LSC
shared signature (Krivtsov et al., 2006), defined by transcripts
with high-level coexpression in normal KSL cells and MLL-AF9
LSCs but low-level expression in committed myeloid progenitors
(CMP, GMP, and MEP), which likely represents anMLL leukemia
initiation program. Thus, the genetic programs required for
leukemia initiation may be quite distinct from those that function
to maintain LSCs within the self-renewing fraction and regulate
their differentiation. It appears that a critical function of the
MLL oncoprotein, through its subordinate effecters Hoxa and
Meis1, is to transmute a normal midmyeloid lineage transcrip-
tional program into an LSC maintenance program that is not
synonymous with an adult stem cell program.
The Nexus ofMLL LSCs, ESCs, Myeloid Progenitors,
and Poor-Prognosis Human Malignancies
Module map analysis indicates that stem cell expression
programs are clustered into two distinct categories, ESC-like
programs versus adult tissue stem cell-like programs (Wong
et al., 2008), and that there is likely not a shared program for
self-renewal in all types of stem cells, in contrast to previous
suggestions (Ivanova et al., 2002). Expression of ESC-like core
program genes is substantially enriched in self-renewing ESCs
and MLL LSCs, as well as in diverse poor-prognosis, poorly
differentiated human malignancies, which may contain frequent
CSCs. However, our analyses also showed transient upregula-
tion of ESC-like program genes during normal myeloid differen-
tiation, with inverse regulation of adult stem cell core program
genes, emphasizing that these dissimilar programs are not
necessarily specific to self-renewing cells.
The ESC-like state in MLL LSCs was not mediated by Nanog,
Pou5f1, orSox2, critical regulators of ESC fate that are not signif-
icantly expressed in MLL LSCs. Nor was it directly controlled by
Myc, which induces the ESC-like signature and regulates CSC
frequency in experimentally induced human epithelial tumors
(Wong et al., 2008), because LSC frequencies across distinct
MLL leukemia subtypes did not correlate significantly with its
expression (data not shown).
We propose a unifying model whereby the ESC-like program,
which coordinately maintains proliferation and inhibits differenti-
ation, is subordinate to diverse upstream regulators that critically
sustain its expression. Upstream positive regulators of the
program might include Nanog, Pou5f1, and Sox2 in ESCs; Myc
in experimentally induced human skin cancer (Wong et al.,
2008); and Hoxa/Meis in MLL LSCs. This model is supported
by our finding that coexpression of Myb, Hmgb3, and Cbx5,
genes that are expressed in both ESCs and MLL LSCs, is suffi-
cient to induce Hoxa/Meis-independent immortalization of
myeloid progenitors. Although expression of the ESC-like
program is induced during normal myeloid differentiation, the
absence of sustained Hoxa/Meis expression in committed
myeloid progenitors/precursors may permit its downregulation,
allowing terminal differentiation. Conversely, an inability to nor-
mally extinguish the ESC-like program in hematopoietic progen-
itors is leukemogenic. This tentative model pathogenically links
inappropriate expression of the initiating MLL/Hox/Meis subpro-138 Cell Stem Cell 4, 129–140, February 6, 2009 ª2009 Elsevier Inc.gram, which is typically a feature of HSCs, with a downstream
ESC-like program in maintaining the aberrant self-renewal of
myeloid progenitors that serve as LSCs in MLL-associated
AML, although how the two programs interlink is not clear.
The co-ordinate expression of ESC-like genes, rather than
adult stem cell program genes, in poor-prognosis human malig-
nancies and MLL LSCs further suggests that the frequency of
CSCs may be more generally linked to prognosis than previously
appreciated, and that these cells are more akin to aberrantly self-
renewing downstream tissue progenitor cells than their normal
tissue stem cell counterparts. Consistent with this possibility,
adverse clinical outcome in human AML correlates with the ability
of AML cells to engraft immune-deficient mice (Pearce et al.,
2006), a functional assay for LSC potential that may also measure
their relative frequencies. Furthermore, human AML cells with
downstream progenitor cell immunophenotypes are able to
initiate leukemia in immune-deficient mice (Taussig et al., 2008).
Cooperative Roles of LSC Maintenance Genes
as Downstream Effecters inMLL Leukemogenesis
Knockdown of upregulated LSC maintenance program genes
(Myb, Hmgb3, and Cbx5) abrogated AML CFC/LSC potential in
proportion to the extent of knockdown, validating their individual
contributions. Furthermore, their simultaneous coexpression
robustly induced BM stem and progenitor cell immortalization
independent of Hoxa/Meis1, whereas expression of the genes
individually did not. These results illustrate the cooperative and
essential nature of an ESC-like LSC maintenance program,
which lies downstream of the initiating MLL oncogene and its
Hoxa/Meis1 effecters.
Although Hmgb3 regulates self-renewal in HSCs (Nemeth
et al., 2006), and is frequently highly expressed in poor-prog-
nosis breast cancer (Ben-Porath et al., 2008), the mechanisms
by which it collaborates with Myb, a key regulator of normal
and leukemic hematopoiesis (Ramsay and Gonda, 2008), and
Cbx5, which normally functions to promote formation of hetero-
chromatin, to mediate LSC maintenance are currently unclear.
Furthermore, it is also unclear whether downregulation of LSC
maintenance program genes in vivo, which permits LSC differen-
tiation and loss of self-renewal, is stochastic or deterministic.
Nevertheless, our findings emphasize the potential for thera-
peutic approaches that target genes and pathways that are of
greater importance to the function of LSCs than HSCs, since
LSCs in this model are distinguished by biological differences
from normal HSCs, which are necessary for regeneration of
hematopoiesis following chemotherapy.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6 mice were purchased from either Jackson Laboratories (Bar Harbor,
Maine) or the Stanford University Research Animal Facility and maintained on
an inbred background. For experiments requiring use of congenic marker anal-
ysis, B6.SJL-Ptprca Pepcb/BoyJ mice, purchased from Jackson Laboratories,
were used as transplant recipients. All experiments on mice in this study were
performed with the approval of and in accordance with Stanford University’s
Administrative Panel on Laboratory Animal Care.
Plasmids
Retroviral vectors containing MLL-ENL (Lavau et al., 1997),MLL-AF10 (DiMar-
tino et al., 2002), MLL-GAS7 (So et al., 2003a), MLL-AF1p (So et al., 2003b),
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Hierarchical Maintenance of MLL LSCsMLL-ENL-ER (Ayton and Cleary, 2003) (all in pMSCV Neo), or MLL-AF9
(pMSCV Puro; Somervaille and Cleary, 2006), and preparation of retroviral
supernatants, have been previously described. Other retroviral vectors used
included the following: HA-Cbx5 (NM_007626) in pMSCVNeo; Myc-tagged
Myb (NM_010848) in pMSCVPuro; and HA-Hmgb3 (NM_008253), HA-Klf3
(NM_008453), HA-Klf13 (NM_021366) and HA-Smad4 (NM_008540) (all in
pMSCV-ires-GFP). The pSicoR lentiviral vector (Ventura et al., 2004) was
adapted to express the monomeric red fluorescent protein mCherry (Shaner
et al., 2004). shRNAs were designed using pSicoOligomaker v1.5 (http://web.
mit.edu/ccr/labs/jacks/protocols/pSico.html), and sequences are listed in
Table S10. Lentiviral supernatants were manufactured as described (Wong
et al., 2007).
BM Stem/Progenitor Cell Transduction, Transplantation,
and Colony-Forming Assays
C-kit+ BM stem and progenitor cells were isolated from donor mice and trans-
duced with retroviruses as previously described (Somervaille and Cleary, 2006).
For triple transductions, BM cells were spinoculated sequentially with each retro-
viral supernatant for 30 min at 32C and 1350 g. Transduced cells (3–10 3 105)
were transplanted by retro-orbital injection immediately following spinoculation
into lethally irradiated (900 cGy) syngeneic recipient mice, together with an addi-
tional radioprotective dose of 23 105 nucleated whole BM cells. An aliquot of the
postspinoculation cells was cultured in methylcellulose medium with 20 ng/ml
SCF, 10 ng/ml IL-6, 10 ng/ml GM-CSF, and 10 ng/ml IL-3 (Peprotech, Rocky
Hill, New Jersey), in the presence or absence of G418 or puromycin drug selec-
tion, to determine retrospectively the transplanted dose of transduced CFCs.
For congenic transplantation analyses, postspinoculation CD45.2+ cells
were serially replated in semisolid culture for three rounds, as previously
described (Somervaille and Cleary, 2006). Pooled, washed cells (8 3 105)
were then transplanted into sublethally irradiated CD45.1+ recipients (450 cGy).
For mouse leukemia CFC assays and limit dilution secondary transplanta-
tion assays, splenocytes frozen in 10% DMSO were thawed and then rested
in RPMI with 20% fetal calf serum and 20% WEHI-conditioned medium for
4 hr. FACS-sorted Mac1+ PI cells were then plated in semisolid culture, as
above, for 6 days prior to colony enumeration or injected immediately in
varying doses into sublethally irradiated syngeneic recipients. For secondary
transplantation of cells derived from a single AML CFC, individual AML colo-
nies were plucked from semisolid culture after 5 days and replated once,
and then, after a further 5 days, 2.5 3 105 cells were washed and injected
into sublethally irradiated syngeneic recipients. For secondary transplantation
of AML cells transduced with Myb knockdown or control lentiviruses, cells
were sorted by FACS 48 hr following transduction for red fluorescence and
then transplanted into sublethally irradiated syngeneic mice.
Flow Cytometry
Analyses were performed, as previously described (Somervaille and Cleary,
2006), using an LSR Model 1a flow cytometer (BD Biosciences, San Jose,
California). Some analyses and all cell-sorting experiments were performed
using a dual-laser FACS Vantage (BD Biosciences). The following antibodies
were used (from eBioscience, San Diego, California, or BD Biosciences
where indicated): Mac1-FITC (eBioscience) or Cy7APC (BD Biosciences) (clone
M1/70), Gr1-PE or Cy7PE (clone RB6-8C5, eBioscience), c-kit-APC (clone 2B8,
eBioscience), F4/80-PE (Caltag Laboratories, Burlingame, California), CD45.2-
FITC (clone 104; BD Biosciences), and CD45.1-PE (clone A20; BD Biosciences).
Quantitative Polymerase Chain Reaction Assays
Quantitative PCR was performed as described (Somervaille and Cleary,
2006) using the following primer sets from Applied Biosystems (Foster City,
California): Myb (Mm00501741_m1), Cbx5 (Mm00483092_m1), Hmgb3
(Mm01281712_g1), Hoxa7 (Mm00657963_m1), Hoxa9 (Mm00439364_m1),
Meis1 (Mm00487664_m1) and Actb (Mm00607939_s1).
Microarray and Bioinformatics Analyses
For whole MLL leukemias, RNA was extracted from at least 5 3 106 BM
leukemia cells by using Trizol reagent according to the manufacturer’s instruc-
tions (Invitrogen, Carlsbad, California). For sortedMLL-AF10 leukemia cell and
normal myeloid cell subpopulations, RNA was prepared using an RNeasy Mini
kit (QIAGEN, Valencia, California). RNA quality was confirmed using an AgilentC2100 bioanalyzer (Agilent Technologies, Santa Clara, California). For whole
MLL leukemias, cDNA and cRNA were synthesized, fragmented, and hybrid-
ized to Affymetrix Mouse Genome 430 2.0 microarrays (Affymetrix, Santa
Clara, CA) according to manufacturer’s instructions. For sorted MLL-AF10
leukemia cell and normal myeloid cell subpopulations, RNA was amplified
using a GeneChip Two-Cycle Target Labeling and Control Reagents kit (Affy-
metrix), and cRNA was hybridized to Affymetrix Mouse Genome 430 2.0 micro-
arrays (Affymetrix), as per the manufacturer’s instructions. Hybridized chips
were scanned by using the GeneChip Scanner 3000, with GeneChip operating
software (v1.1.1) (Affymetrix). Raw data are available for download from Gene
Expression Omnibus (GSE13690; GSE13692; GSE13693).
Whole MLL leukemia BM data sets were normalized using Microarray Anal-
ysis Software v5.0 (Affymetrix). All other normalizations (including downloaded
CEL file data from Krivtsov et al. [2006]), together with all data set comparisons
and cluster analyses, were performed using dChip 2007 (DNA-Chip Analyzer)
software (Li and Wong, 2001; http://biosun1.harvard.edu/complab/dchip/
manual.htm). A perfect match/mismatch (PM/MM) model was used for the
calculation of expression values. Differentially regulated probe sets in whole
MLL leukemias, and in sorted leukemia cell subpopulations, were determined
using p% 0.01 (unpaired t test) as the sole comparison criterion. Median FDR
was assessed using 1000 data permutations. Probe set lists were intersected
using a web-based tool (http://jura.wi.mit.edu/bioc/tools/compare.html). For
certain analyses, expression values for defined gene sets were extracted
from normalized data sets using the Excel function VLOOKUP. Unsupervised
cluster analysis, with masking of redundant probe sets to exclude gene dupli-
cates, was performed using the resultant tab-delimited text files. HUGO gene
names of core ESC-like gene module genes and adult stem cell tissue module
genes were converted into 430 2.0 Affymetrix probe set identifiers using
a webtool (http://www.affymetrix.com).
GO analysis was performed using MGI Gene Ontology Term Finder (http://
proto.informatics.jax.org/prototypes/GOTools/web-docs/MGI_Term_Finder.
html).
Gene set enrichment analyses (Subramanian et al., 2005) were performed
using GSEA v2.0 software (http://www.broad.mit.edu/gsea) with a tTest metric
for gene ranking and 1000 data permutations.
SUPPLEMENTAL DATA
The Supplemental Data include seven figures and ten tables and can be found
with this article online at http://www.cell.com/cell-stem-cell/supplemental/
S1934-5909(08)00617-6.
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